zhigang wang

Prof. zhigang wang


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2018 in ACS Nano
Verified
Journal Article
Closed access
XHXiaoxia Han
Xiaoxia Han
JHJu Huang
Ju Huang
XJXiangxiang Jing
Xiangxiang Jing
DYDayan Yang
Dayan Yang
HLHan Lin
Han Lin
Yu ChenYu Chen
Yu Chen

1 May 2018 in Biomaterials
Verified
Journal Article
Closed access
DSDanli Sheng
Danli Sheng
TLTianzhi Liu
Tianzhi Liu
LDLiming Deng
Liming Deng
LZLiang Zhang
Liang Zhang
XLXuelin Li
Xuelin Li
ZWzhigang wang
zhigang wang

8 February 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LZLiang Zhang
Liang Zhang
HYHengjing Yi
Hengjing Yi
JSJiao Song
Jiao Song
JHJu Huang
Ju Huang
KYKe Yang
Ke Yang
XLXingsheng Li
Xingsheng Li

11 March 2019 in ACS Nano
Verified
Journal Article
Closed access
YZYixin Zhong
Yixin Zhong
YZYu Zhang
Yu Zhang
JXJie Xu
Jie Xu
JZJun Zhou
Jun Zhou
JLJia Liu
Jia Liu
DGDajing Guo
Dajing Guo

6 May 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JLJunzhao Liu
Junzhao Liu
ZWZuohong Wu
Zuohong Wu
YLYadong Liu
Yadong Liu
ZZZhu Zhan
Zhu Zhan
LYLiping Yang
Liping Yang
ZWzhigang wang
zhigang wang
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic disease with pathophysiological characteristics of transforming growth factor-β (TGF-β), and reactive oxygen species (ROS)-induced excessive fibroblast-to-myofibroblast transition and extracellular matrix deposition. Macrophages are closely involved in the development of fibrosis. Nuclear factor erythroid 2 related factor 2 (Nrf2) is a key molecule regulating ROS and TGF-β expression. Therefore, Nrf2 signaling modulation might be a promising therapy for fibrosis. The inhalation-based drug delivery can reduce systemic side effects and improve therapeutic effects, and is currently receiving increasing attention, but direct inhaled drugs are easily cleared and difficult to exert their efficacy. Therefore, we aimed to design a ROS-responsive liposome for the Nrf2 agonist dimethyl fumarate (DMF) delivery in the fibrotic lung. Moreover, we explored its therapeutic effect on pulmonary fibrosis and macrophage activation.Results: We synthesized DMF-loaded ROS-responsive DSPE-TK-PEG@DMF liposomes (DTP@DMF NPs). DTP@DMF NPs had suitable size and negative zeta potential and excellent capability to rapidly release DMF in a high-ROS environment. We found that macrophage accumulation and polarization were closely related to fibrosis development, while DTP@DMF NPs could attenuate macrophage activity and fibrosis in mice. RAW264.7 and NIH-3T3 cells coculture revealed that DTP@DMF NPs could promote Nrf2 and downstream heme oxygenase-1 (HO-1) expression and suppress TGF-β and ROS production in macrophages, thereby reducing fibroblast-to-myofibroblast transition and collagen production by NIH-3T3 cells. In vivo experiments confirmed the above findings. Compared with direct DMF instillation, DTP@DMF NPs treatment presented enhanced antifibrotic effect. DTP@DMF NPs also had a prolonged residence time in the lung as well as excellent biocompatibility.Conclusions: DTP@DMF NPs can reduce macrophage-mediated fibroblast-to-myofibroblast transition and extracellular matrix deposition to attenuate lung fibrosis by upregulating Nrf2 signaling. This ROS-responsive liposome is clinically promising as an ideal delivery system for inhaled drug delivery.Graphical

28 January 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HCHong-Bo Cheng
Hong-Bo Cheng
BQBin Qiao
Bin Qiao
HLHao Li
Hao Li
JCJin Cao
Jin Cao
YLYuanli Luo
Yuanli Luo
JYJuyoung Yoon
Juyoung Yoon